Lieke Hol

Papers

Total Citations

H-Index

About

Dr. Lieke Hol is a leading clinical researcher in radiation oncology, specializing in stereotactic body radiotherapy (SBRT) for abdominopelvic oligometastases. Her work focuses on understanding and mitigating gastrointestinal toxicity, a critical challenge in delivering high-dose radiation to metastatic tumors outside the liver. In her most cited study (2017, 5 citations), Hol pioneered the correlation of dose-volume histogram (DVH) parameters with acute and late grade ≥2 bowel toxicity following robotic SBRT. This research provided essential dosimetric constraints to guide safer treatment planning, directly impacting clinical protocols for patients with solitary or oligometastatic disease. By systematically analyzing toxicity outcomes, Hol’s contributions help balance effective tumor control with reduced patient morbidity. Her work is foundational for radiation oncologists seeking to optimize SBRT delivery in the abdomen and pelvis, and it underscores her commitment to improving therapeutic ratios in advanced radiotherapy. Hol’s research continues to influence evidence-based practice, making her a respected voice in the field of stereotactic radiation and normal tissue complication modeling.